A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia (Certolizumab Pegol)

Trial Profile

A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia (Certolizumab Pegol)

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Spondylitis
  • Focus Pharmacokinetics
  • Acronyms CRIB
  • Sponsors UCB
  • Most Recent Events

    • 06 Nov 2017 According to a UCB media release, results from this trial will be presented at the 2017 American College of Rheumatology/Association for Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.
    • 13 Oct 2017 Results published in the Annals of the Rheumatic Diseases
    • 14 Sep 2017 According to an UCB media release, data from the study were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top